Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs
- 15 September 2009
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (18), 5444-5448
- https://doi.org/10.1016/j.bmcl.2009.07.118
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Ritonavir–PEG 8000Amorphous Solid Dispersions: In vitro and In vivo EvaluationsJournal of Pharmaceutical Sciences, 2004
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- A Review of Low-Dose Ritonavir in Protease Inhibitor Combination TherapyClinical Infectious Diseases, 2003
- Lopinavir/RitonavirDrugs, 2003
- Lopinavir/ritonavir (ABT-378/r)Expert Opinion on Pharmacotherapy, 2002
- Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV InfectionClinical Pharmacokinetics, 2002
- RitonavirClinical Pharmacokinetics, 1998
- Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: Major role of CYP3ABiochemical Pharmacology, 1997
- Macrolide AntibacterialsDrug Safety, 1995
- Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseAntimicrobial Agents and Chemotherapy, 1991